Efficacy and Safety of Ceftazidime-Avibactam (CAZ-AVI) in Chinese Participants With HAP (Including VAP)

PHASE4CompletedINTERVENTIONAL
Enrollment

235

Participants

Timeline

Start Date

May 21, 2021

Primary Completion Date

May 4, 2023

Study Completion Date

May 4, 2023

Conditions
Hospital-Acquired Pneumonia
Interventions
DRUG

Zavicefta, Ceftazidime-Avibactam

Participants will receive CAZ-AVI (2000 mg of ceftazidime and 500 mg of avibactam) administered by IV infusion in a volume of 100 mL at a constant rate over 2 hours.

Trial Locations (56)

47300

NanYang First people's hospital, Nanyang

100191

Peking University Third Hospital, Beijing

110016

General Hospital of Northern Theater Command, Shenyang

116001

Affiliated Zhongshan Hospital of Dalian University, Dalian

200040

Huashan Hospital Fudan University, Shanghai

200240

Shanghai Fifth People's Hospital, Fudan University, Shanghai

214122

Affiliated Hospital of Jiangnan University, Wuxi

214400

Jiangyin People's Hospital, Jiangyin

221002

The Affiliated Hospital of Xuzhou Medical University, Xuzhou

222002

The First People's Hospital of Lianyungang City, Lianyungang

223300

Huai'an First People's Hospital, Huai'an

225001

Subei People's Hospital of Jiangsu province, Yangzhou

225300

Taizhou People's Hospital, Taizhou

236000

Fuyang People's Hospital, Fuyang

300052

Tianjin Medical University General Hospital, Tianjin

300222

Tianjin Chest Hospital, Tianjin

310013

Zhejiang Hospital, Hangzhou

310014

Zhejiang Provincial People's Hospital, Hangzhou

310016

Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou

310030

Zhejiang Hospital, Hangzhou

322199

Dongyang People's Hospital, Dongyang

325035

The 2nd Affiliated Hospital of WMU, Wenzhou

325099

Wenzhou Central Hospital, Wenzhou

330038

Jiangxi Provincial People's Hospital, Nanchang

350005

The First Affiliated Hospital of Fujian Medical University, Fuzhou

361004

Zhongshan Hospital Xiamen University, Xiamen

410005

Hunan Provincial People's Hospital, Changsha

414020

Yueyang People's Hospital, Yueyang

430058

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

430060

Renmin Hospital of Wuhan University, Wuhan

442000

Shiyan Renmin Hospital, Shiyan

450003

Henan provincial people's hospital, Zhengzhou

471009

Luoyang Central Hospital, Luoyang

473000

NanYang central hospital, Nanyang

510180

Guangzhou First People's Hospital, Guangzhou

510280

ZhuJiang Hospital of Southern Medical University, Guangzhou

510630

The First Affiliated Hospital of Jinan University, Guangzhou

511500

Qingyuan People's Hospital, Qingyuan

516008

Huizhou Central People's Hospital, Huizhou

518020

Shenzhen People's Hospital, Shenzhen

518035

The Second People's Hospital of Shenzhen, Shenzhen

524000

Affiliated Hospital of Guangdong Medical University, Zhanjiang

524045

Central People's Hospital of Zhanjiang, Zhanjiang

530022

The First People's Hospital of Nanning, Nanning

563000

The Affiliated Hospital of Zunyi Medical University, Zunyi

570311

Hainan General Hospital, Haikou

572022

Sanya People's Hospital, Sanya

610041

West China Hospital of Sichuan University, Chengdu

610055

Chengdu Xinhua Hospital, Chengdu

650034

The First Hospital of Kunming, Kunming

750004

General Hospital of Ningxia Medical University, Yinchuan

071000

Affiliated Hospital of Hebei University, Baoding

014000

Baotou Central Hospital, Baotou

014040

Baotou Central Hospital, Baotou

Unknown

Seventh Medical Center, The General Hospital of People's Liberation Army, Beijing

Zhongshan Hospital Xiamen University, Xiamen

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT04774094 - Efficacy and Safety of Ceftazidime-Avibactam (CAZ-AVI) in Chinese Participants With HAP (Including VAP) | Biotech Hunter | Biotech Hunter